The AAO is largely supportive of the bill, S. 959, but calls for exemption from provisions that require specific patient designation for biological products and marketed drugs. The Academy argues there is no evidence linking safe repackaging processes with the use of a patient’s name when labeling a drug.
More Articles on Ophthalmology:
Dr. Judy Meyers Joins Ophthalmology Associates in Fort Worth
ARVO Names Dr. Justine Smith President, Dr. William Mieler President-Elect
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
